Plasma DYRK1A as a novel risk factor for Alzheimer's disease

Translational Psychiatry

Volumn 4, Issue , 2011, Pages

  Janel, N ^a   Sarazin, M ^b   Corlier, F ^c,d,e   Corne, H ^c,d   De Souza, L C ^c,d,e   Hamelin, L ^b   Aka, A ^a   Lagarde, J ^b   Blehaut, H ^f   Hindie V ^g   Rain, J C ^g   Arbones, M L ^h   Dubois, B ^c,d   Potier, M C ^d   Bottlaender, M ⁱ   Delabar, J M ^a  

^a Groupe Hospitalier Pitié Salpêtrière   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f Institut Jerome Lejeune   (France)

^g Hybrigenics SA   (France)

^h INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

ⁱ SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; DYRK1A PROTEIN; DYRK1B PROTEIN; PITTSBURGH COMPOUND B; PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; BRAIN ENZYME; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A; PHOSPHOPROTEIN; PHOSPHOPROTEIN TAU;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BRAIN REGION; BRAIN TISSUE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; EXPERIMENTAL ANIMAL; FEMALE; GENE DOSAGE; GENOTYPE; HUMAN; IMMUNOBLOTTING; LYMPHOBLASTOID CELL LINE; MALE; MOUSE; NONHUMAN; PATIENT RISK; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RISK ASSESSMENT; RISK FACTOR; TRANSGENIC MOUSE; AGE; ANIMAL MODEL; ANIMAL TISSUE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN BINDING;

EID: 84907334306     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.61     Document Type: Article

References (30)

1. Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P et al. Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov 2012; 11: 833-846.
2. Jack CR Jr., Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 257-262.
3. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
4. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011; 377: 1019-1031.
5. Smith B, Medda F, Gokhale V, Dunckley T, Hulme C. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? ACS Chem Neurosci 2012; 3: 857-872.
6. Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem J 2001; 355: 609-615.
7. Sheppard O, Plattner F, Rubin A, Slender A, Linehan JM, Brandner S et al. Altered regulation of tau phosphorylation in a mouse model of down syndrome aging. Neurobiol Aging 2012; 33: 828.e31-828.e44.
8. Liu F, Liang Z, Wegiel J, Hwang YW, Iqbal K, Grundke-Iqbal I et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J 2008; 22: 3224-3233.
9. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H et al. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 2007; 16: 15-23.
10. Korenberg JR, Aaltonen J, Brahe C, Cabin D, Creau N, Delabar JM et al. Report and abstracts of the Sixth International Workshop on Human Chromosome 21 Mapping 1996. Cold Spring Harbor, New York, USA. May 6-8,1996.
11. Cytogenet Cell Genet 1997; 79: 21-52.
12. Guedj F, Pereira PL, Najas S, Barallobre MJ, Chabert C, Souchet B et al. DYRK1A: a master regulatory protein controlling brain growth. Neurobiol Dis 2012; 46: 190-203.
13. Tlili A, Hoischen A, Ripoll C, Benabou E, Badel A, Ronan A et al. BDNF and DYRK1A are variable and inversely correlated in lymphoblastoid cell lines from Down syndrome patients. Mol Neurobiol 2012; 46: 297-303.
14. Jenne DE, Lowin B, Peitsch MC, Bottcher A, Schmitz G, Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 1991; 266: 11030-11036.
15. Fotaki V, Dierssen M, Alcantara S, Martinez S, Marti E, Casas C et al. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol Cell Biol 2002; 22: 6636-6647.
16. Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 2007; 69: 1859-1867.
17. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8: 619-627.
18. de Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R, Lamari F et al. Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer's disease. Brain 2011; 134: 2036-2043.
19. de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry 2011; 82: 240-246.
20. Deng X, Ewton DZ, Pawlikowski B, Maimone M, Friedman E. Mirk/dyrk1B is a Rhoinduced kinase active in skeletal muscle differentiation. J Biol Chem 2003; 278: 41347-41354.
21. Ferrer I, Barrachina M, Puig B, Martinez de Lagran M, Marti E, Avila J et al. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis 2005; 20: 392-400.
22. Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, Kim YS et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. J Neurochem 2008; 104: 1333-1344.
23. Friedman E. Mirk/Dyrk1B in cancer. J Cell Biochem 2007; 102: 274-279.
24. Liu X, Valentine SJ, Plasencia MD, Trimpin S, Naylor S, Clemmer DE. Mapping the human plasma proteome by SCX-LC-IMS-MS. J Am Soc Mass Spectrom 2007; 18: 1249-1264.
25. Qian W, Jin N, Shi J, Yin X, Jin X, Wang S et al. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) enhances tau expression. J Alzheimers Dis 2013; 37: 529-538.
26. Rachdi L, Kariyawasam D, Guez F, Aiello V, Arbones ML, Janel N et al. Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass. Diabetologia 2014; 57: 960-969.
27. Hamelet J, Couty JP, Crain AM, Noll C, Postic C, Paul JL et al. Calpain activation is required for homocysteine-mediated hepatic degradation of inhibitor I kappa B alpha. Mol Genet Metab 2009; 97: 114-120.
28. Noll C, Tlili A, Ripoll C, Mallet L, Paul JL, Delabar JM et al. Dyrk1a activates antioxidant NQO1 expression through an ERK1/2-Nrf2 dependent mechanism. Mol Genet Metab 2012; 105: 484-488.
29. Tlili A, Jacobs F, Koning LD, Mohamed S, Bui LC, Dairou J et al. Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/ GSK3 pathways in hyperhomocysteinemic mice. Biochim Biophys Acta 2013; 1832: 718-728.
30. Xiang Z, Haroutunian V, Ho L, Purohit D, Pasinetti GM. Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia. Dis Markers 2006; 22: 95-102.